What was the primary driver of Regeneron's revenue growth in this quarter?

The primary driver of revenue growth was the significant increase in EYLEA net product sales in the United States, which rose by 58% year-over-year to $654.6 million. This strong performance, combined with continued growth in collaboration revenues from Sanofi and Bayer HealthCare, fueled the overall 50% increase in total revenues.

What significant regulatory milestones did Regeneron achieve during the quarter?

The most significant regulatory milestone was the FDA approval of Praluent (alirocumab) in July 2015 for the treatment of adults with high LDL cholesterol. This marks the commercial launch of a new product in a key therapeutic area for the company.

How is Regeneron investing in its future growth?

Regeneron is making substantial investments in its future growth through robust research and development activities. R&D expenses increased by 33% year-over-year to $390.3 million in the second quarter, indicating a strong commitment to advancing its pipeline of antibody candidates and other therapeutic programs.

What is the company's current financial position and liquidity?

Regeneron maintained a strong financial position with $390.6 million in cash and cash equivalents and $803.3 million in marketable securities as of June 30, 2015. The company also had access to a $750 million revolving credit facility, with no outstanding borrowings, providing significant financial flexibility.

REGN 10-Q Quarterly Report Q2 FY2015 — Revenue, Net Income, EPS

Summary

Regeneron Pharmaceuticals, Inc. reported strong financial results for the quarter ended June 30, 2015, driven by significant growth in EYLEA net product sales, which increased by 58% year-over-year to $654.6 million. Total revenues grew 50% to $998.6 million, and net income more than doubled to $194.6 million. The company's strategic collaborations with Sanofi and Bayer HealthCare continue to be a major revenue driver, with Sanofi collaboration revenue up 37% and Bayer HealthCare collaboration revenue up 38% in the quarter. The company also made significant progress in its pipeline, with the FDA approving Praluent (alirocumab) for the treatment of high LDL cholesterol in July 2015. This approval, coupled with robust clinical trial data for other pipeline candidates like dupilumab and sarilumab, indicates a promising future for Regeneron. The company's ongoing investment in research and development remains high, reflecting its commitment to innovation and future growth, supported by a substantial cash position and an undrawn credit facility.

Financial Highlights

46 data points

Beta

Revenue

$998.62M

0.9% Gross Margin

Net Income

$194.64M

0.2% Net Margin

EPS (Diluted)

$1.69

Total Assets

$4.53B

Cash & Equivalents

$390.55M

Free Cash Flow

$257.83M

Financial Statements

Beta

Revenue	$998.62M
Cost of Revenue	$60.85M
Gross Profit	$937.76M
R&D Expenses	$390.33M
SG&A Expenses	$174.59M
Operating Expenses	$653.76M
Operating Income	$344.86M
Interest Expense	$2.75M
Net Income	$194.64M
EPS (Basic)	$1.89
EPS (Diluted)	$1.69
Shares Outstanding (Basic)	102.89M
Shares Outstanding (Diluted)	115.26M

Key Highlights

1EYLEA net product sales increased by 58% to $654.6 million in Q2 2015 compared to Q2 2014.
2Total revenues for Q2 2015 grew 50% year-over-year to $998.6 million.
3Net income more than doubled in Q2 2015, reaching $194.6 million, compared to $96.3 million in Q2 2014.
4Sanofi collaboration revenue increased by 37% to $195.1 million in Q2 2015.
5Bayer HealthCare collaboration revenue rose by 38% to $134.2 million in Q2 2015.
6Praluent (alirocumab) received FDA approval in July 2015 for treating high LDL cholesterol.
7Research and development expenses increased by 33% to $390.3 million in Q2 2015, reflecting continued investment in the pipeline.

REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q2 Ended Jun 30, 2015

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions